These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29088743)

  • 1.
    Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
    Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
    Fujimura T; Furugaki K; Harada N; Yoshimura Y
    Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
    Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
    Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
    Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
    J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
    Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
    J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic characteristics and diagnostic methods of
    Feng J; Li Y; Wei B; Guo L; Li W; Xia Q; Zhao C; Zheng J; Zhao J; Sun R; Guo Y; Brcic L; Hakozaki T; Ying J; Ma J
    Transl Lung Cancer Res; 2022 Apr; 11(4):617-631. PubMed ID: 35529790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
    Gozgit JM; Chen TH; Song Y; Wardwell S; Wang F; Cai J; Li H; Edgren H; Rivera VM; Pritchard J
    Oncotarget; 2018 Jul; 9(51):29654-29664. PubMed ID: 30038711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
    Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
    Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
    Takeuchi S; Yanagitani N; Seto T; Hattori Y; Ohashi K; Morise M; Matsumoto S; Yoh K; Goto K; Nishio M; Takahara S; Kawakami T; Imai Y; Yoshimura K; Tanimoto A; Nishiyama A; Murayama T; Yano S
    Transl Lung Cancer Res; 2021 Jan; 10(1):314-325. PubMed ID: 33569315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.
    O'Leary C; Xu W; Pavlakis N; Richard D; O'Byrne K
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.
    Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Viteri S; d'Hondt E; Rosell R
    Transl Oncol; 2021 Jan; 14(1):100887. PubMed ID: 33129112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.
    Kim SY; Oh SO; Kim K; Lee J; Kang S; Kim KM; Lee W; Kim ST; Nam DN
    J Cancer; 2018; 9(17):3032-3037. PubMed ID: 30210625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
    Nagasaka M; Brazel D; Baca Y; Xiu J; Al-Hallak MN; Kim C; Nieva J; Swensen JJ; Spetzler D; Korn WM; Socinski MA; Raez LE; Halmos B; Ou SI
    Transl Oncol; 2023 Oct; 36():101744. PubMed ID: 37516008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
    Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
    Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.